 Hello Immunization Partners,
Please share the following information with staff and colleagues.
On May 3rd MDHHS sent out an email regarding the recently published MMWR regarding use of Penbraya-MenABCWY, Pentavalent Meningococcal Vaccine from Pfizer. The Division of Immunization’s Education team has additional clinical points to share regarding the use of Penbraya.
- When both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit then Penbraya-MenABCWY may be administered for:
- Healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine.
- Persons aged 10 years and older who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).
- Penbraya is a pentavalent vaccine made up of a MenACWY component and a MenB component:
- The MenACWY component is Nimenrix™ (MenACWY-TT).
- The MenB component is Trumenba® (MenB-FHbp).
- The MenB component of Penbraya determines the MenB vaccine you should have in inventory for use to administer to help complete the MenB vaccine series.
- If you stock Penbraya, this point should be considered when ordering MenB vaccine.
- If Penbraya is used, which includes Trumenba®, then administer:
- Trumenba® for additional MenB dose(s) when MenACWY is not indicated.
- For example: Healthy adolescents and young adults aged 16–23 years who receive one dose of Penbraya based on shared clinical decision-making should complete the MenB series with a dose of Trumenba (MenB-FHbp) six months after the pentavalent vaccine dose was administered.
- Remember, MenB vaccines are not interchangeable, if Penbraya is administered subsequent doses of MenB should be from the same manufacturer (Trumenba-Pfizer Inc). Bexsero should not be used.
- Penbraya may be administered only if both MenACWY and MenB vaccines are indicated at the same visit.
- Otherwise, MenACWY and MenB vaccines should be given separately as appropriate.
- The minimum interval between MenABCWY doses is 6 months.
- Persons at increased risk for meningococcal disease who receive a dose of Penbraya and are recommended to receive additional doses of MenACWY and MenB less than 6 months after a dose of Penbraya, should receive separate MenACWY and MenB (Trumenba) vaccines rather than Penbraya.
- At this time, Penbraya is not recommended:
- For the 11 to 12-year-old dose (only need MenACWY).
- For the second MenB dose.
- People with prolonged, increased risk for serogroup A, C, W, or Y and B meningococcal disease need regular boosters. The recommended interval between doses varies by age and vaccine type. Two great meningococcal vaccine resources for vaccinating those at high risk:
- Penbraya is supplied in a kit that includes a vial of lyophilized MenACWY component (a sterile white powder), a pre-filled syringe containing the MenB component and a vial adapter, and it can be ordered in quantities of one or five doses
The Advisory Committee on Immunization Practices (ACIP) is evaluating the current meningococcal vaccine recommendations and may change them in the future. GSK is also working on developing a MenABCWY vaccine.
The above ACIP recommendation was published on April 18, 2024, in the Morbidity and Mortality Weekly Report (MMWR) titled “Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023 | MMWR (cdc.gov).”
Please refer to this report and Meningococcal Vaccine Recommendations | CDC for additional guidance.
Thank you for helping to protect Michiganders from vaccine preventable diseases.
Oakland County Health Division, Immunization Action Plan
|
